Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

Study ID
NCT00884767

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity. PURPOSE: This phase II trial is studying biomarkers in predicting neurotoxicity in patients with colorectal cancer receiving oxaliplatin.

More informations

Trial Starting Date

Sep 30,2007

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

206